Credit for Increasing Research Activities

The Credit for Increasing Research Activities is a strategic tax incentive that reduces the financial burden of innovation by providing a dollar-for-dollar reduction in tax liability for qualified research expenses. In the context of New York, it represents a multifaceted suite of credits that align state definitions with federal standards to subsidize technological and scientific development performed within the state.

The formal designation “Credit for Increasing Research Activities” (CIRA) originates from Internal Revenue Code (IRC) Section 41, a provision that has served as the bedrock for American innovation policy since its temporary introduction in 1981 and its permanent codification in 2015 via the Protecting Americans from Tax Hikes (PATH) Act. While the federal government provides a nonrefundable credit against income tax—or a payroll tax offset for certain startups—New York State has constructed a more aggressive incentive landscape. The New York R&D tax environment is characterized by its use of fully refundable credits, which provide immediate cash flow to early-stage, pre-revenue companies that lack the tax liability to benefit from traditional nonrefundable credits. This report explores the definition of the CIRA, its intersection with New York’s specific statutory programs, the detailed guidance provided by the New York Department of Taxation and Finance (DTF), and the administrative requirements enforced by Empire State Development (ESD).

The Statutory Foundation: IRC Section 41 and the Federal Framework

To comprehend the New York R&D credit, one must first master the federal framework established by IRC Section 41. The federal CIRA is an incremental credit, meaning it is generally designed to reward businesses for increasing their research spending relative to a historical base period. The definition of “qualified research” is rigorous and is governed by a statutory “four-part test.” This test serves as the gatekeeper for all federal and most state R&D tax incentives, ensuring that the credit subsidizes genuine technological experimentation rather than routine engineering or aesthetic design.

The Foundational Four-Part Test

For an activity to qualify as research under Section 41, it must satisfy each of the following criteria:

The research must be undertaken for a “permitted purpose,” which involves the development of a new or improved business component. A business component is defined as any product, process, computer software, technique, formula, or invention that the taxpayer intends to hold for sale, lease, or license, or use in its own trade or business. The objective must be to achieve a measurable improvement in the functionality, performance, reliability, quality, or durability of that component.

The research must be intended to discover information that is “technological in nature.” This means the activity must fundamentally rely on the principles of the “hard sciences,” such as engineering, biological science, physical science, or computer science. Activities based on the social sciences, humanities, or management studies are explicitly excluded from the definition of qualified research.

The taxpayer must face “technical uncertainty” at the outset of the project. Uncertainty exists if the information available to the taxpayer does not establish the capability of achieving the desired result, the method for achieving it, or the appropriate design of the business component. This uncertainty must be technical rather than commercial; for instance, uncertainty about whether a product will sell is not a qualifying uncertainty.

Substantially all of the activities associated with the research project must constitute elements of a “process of experimentation.” This requires a systematic evaluative process where the taxpayer identifies one or more alternatives to eliminate the technical uncertainty and uses iterative methods—such as modeling, simulation, prototyping, and trial-and-error testing—to evaluate those alternatives.

Qualified Research Expenses (QREs)

Once an activity passes the four-part test, the associated costs can be categorized as Qualified Research Expenses (QREs). Under federal law, these expenses are limited to specific domestic costs directly connected to the research effort.

New York state law generally adopts these federal definitions of QREs, though specific programs may modify them. For instance, the Life Sciences Research and Development Tax Credit explicitly excludes contract research expenses, emphasizing the state’s policy goal of incentivizing in-house employment and facility growth over outsourced activity.

New York State’s Modular R&D Credit Landscape

New York does not offer a single, blanket R&D credit for all taxpayers. Instead, it has integrated research incentives into several distinct programs, each with its own eligibility criteria, calculation methods, and administrative oversight. The primary mechanisms are the Excelsior Jobs Program R&D Credit, the Life Sciences R&D Credit, and the Qualified Emerging Technology Company (QETC) credits.

The Excelsior Research and Development Tax Credit

The Excelsior Jobs Program is the flagship economic development initiative of New York State. Administered by Empire State Development, it targets firms in strategic industries that make significant commitments to job growth or capital investment.

A participant in the program may claim the Excelsior R&D tax credit component for up to 10 consecutive years. The credit is calculated as 50% of the portion of the taxpayer’s federal R&D tax credit that is attributable to activities conducted in New York. This methodology creates a direct link between the CIRA meaning and New York law; the state benefit is essentially an “add-on” to the federal benefit, but with the critical advantage of full refundability.

The statute provides for specific caps on the credit amount relative to New York research expenditures. These caps reflect the state’s prioritization of high-tech and “green” industries:

To qualify for the standard 6% credit, a firm must operate predominantly in industries such as biotechnology, pharmaceuticals, high-tech, clean-technology, or manufacturing. The “Green Project” designation applies to activities aimed at reducing greenhouse gas emissions or supporting clean energy solutions, which entitles the participant to a higher 8% cap.

The Life Sciences Research and Development Tax Credit

In contrast to the discretionary nature of the Excelsior program, the Life Sciences Research and Development Tax Credit is a non-discretionary program targeted at new life sciences businesses. This program was established to make New York a global hub for biotechnology and pharma innovation by providing immediate cash refunds to startups.

To be eligible, a business must be a “new business” certified as a qualified life sciences company. The new business test is rigorous: the entity must not have operated in New York for more than five years, and it must not be substantially similar in ownership to a current or former New York taxpayer.

The credit is calculated as a fixed percentage of qualified research expenditures incurred in New York, with rates tiered by the size of the workforce:

• 20% Credit: Available for companies with fewer than 10 employees.
• 15% Credit: Available for companies with 10 or more employees.

This credit is allowed for up to three consecutive years and is limited to an annual cap of $500,000 per year, with a $1.5 million lifetime cap per company. Unlike the Excelsior credit, the Life Sciences credit excludes contract research, reinforcing the requirement for a physical innovation presence in the state.

Qualified Emerging Technology Company (QETC) Credits

The QETC framework provides additional layers of support for small, high-growth technology firms. A QETC is defined as a New York business with annual product sales of $10 million or less that meets either a “primary products/services” test or a “research intensity” test. The research intensity test requires the business’s ratio of R&D funds to net sales to equal or exceed the average ratio for all surveyed companies as determined by the National Science Foundation.

Businesses meeting the QETC definition can access the QETC Employment Credit, which offers $1,000 for every new job created over a base period, and the QETC Capital Tax Credit, which incentivizes external investment by offering credits to owners who provide equity capital to these firms.

Local State Revenue Office Guidance and Administrative Procedures

The administration of New York’s R&D tax credits is shared between the Department of Taxation and Finance (DTF) and Empire State Development (ESD). The process generally follows a specific cadence: programmatic application, certification, and tax return filing.

Guidance from Empire State Development (ESD)

ESD serves as the gatekeeper for programmatic entry. For the Excelsior Jobs Program, businesses must submit a Consolidated Funding Application (CFA). The ESD Commissioner exercises significant discretion in admitting firms, basing decisions on the project’s potential economic impact and the firm’s commitment to job and investment targets.

Once admitted, firms must submit an annual performance report to verify that they have met their contractual milestones. Only after this verification does ESD issue a “Certificate of Tax Credit.” This certificate is the primary evidentiary document required by the DTF to process the credit claim.

Guidance from the Department of Taxation and Finance (DTF)

The DTF provides the administrative mechanisms for claiming the credits through specific tax forms and Technical Memoranda (TSB-M). The TSB-Ms are informational statements that clarify changes to the law or department policies.

Key guidance documents for New York R&D credits include:

This memorandum summarizes the increase in the Excelsior R&D credit component from 10% to 50% of the federal credit and the establishment of the statutory caps. It also clarifies that costs used for the Excelsior R&D credit can also be used for the QETC facilities, operations, and training credit, allowing for a degree of “incentive stacking” within the state system.

This memo clarifies the “primary products or services” test for QETCs. It specifies that the mere use of emerging technology is insufficient; the business must be engaged in creating or developing those technologies. It provides a ratio-based method for businesses to prove that more than 50% of their receipts or expenses are attributable to emerging technology activities.

This memo provides the foundational rules for the Life Sciences R&D credit. It defines “qualified life sciences company” and clarifies the “new business” test under Tax Law § 210-b(1)(f). It also confirms that the credit is fully refundable and cannot be used to reduce the tax below the fixed dollar minimum.

Line Instructions and Form Requirements

The DTF mandates the use of specific forms for each credit component. Corporations subject to the franchise tax under Article 9-A must use the “CT” series, while individuals, partnerships, and S-corporation shareholders use the “IT” series.

Instructions for Form CT-648 emphasize that taxpayers must submit a copy of their ESD certificate with their return. Schedule A requires the taxpayer to enter the specific credit amount listed on the certificate, which is capped at $500,000. Schedule B is used by combined filers when multiple members of a group are qualified life sciences companies, ensuring the group-wide cap is not exceeded. Schedule D calculates the credit used, refunded, or applied as an overpayment, following a strict ordering of credits prescribed in Form CT-600-I.

The Section 174 Amortization Crisis and Regulatory Evolution

The value of the New York R&D tax credit is intrinsically tied to the federal treatment of research and experimental (R&E) expenditures under IRC Section 174. Historically, Section 174 allowed businesses to immediately deduct all R&E costs, which lowered federal and state taxable income.

However, the Tax Cuts and Jobs Act (TCJA) of 2017 mandated that for tax years beginning after December 31, 2021, all R&E expenditures must be capitalized and amortized over five years (domestic) or 15 years (foreign). Because New York is a “rolling conformity” state—meaning it automatically adopts federal definitions of adjusted gross income—this change effectively increased New York state taxable income for innovative firms.

Restoration of Expensing via the “One Big Beautiful Bill”

In July 2025, the legislative landscape shifted again with the enactment of the “One Big Beautiful Bill” (OBBB) Act. This reform restored the option to immediately expense domestic R&E expenditures for tax years beginning after December 31, 2024.

Crucially for New York businesses, the OBBB included retroactive transition rules:

The OBBB introduced Section 174A, allowing businesses to once again deduct domestic R&E costs in the year incurred.

Small businesses meeting a $31 million gross receipts test can retroactively apply Section 174A to their 2022–2024 expenditures, potentially triggering massive refunds.

Taxpayers can elect to recover unamortized TCJA Section 174 amounts either fully in 2025 or spread across 2025 and 2026.

These changes impact the New York R&D credit in two ways. First, they lower the “starting point” for state taxable income. Second, since the Excelsior R&D credit is 50% of the federal credit, any recharacterization of expenses at the federal level to comply with these new rules will directly affect the magnitude of the New York credit claim.

Form 6765 and the New Era of Disclosure

While New York’s credits are claimed on state forms, the underlying documentation is increasingly driven by the IRS’s significant revisions to Form 6765, Credit for Increasing Research Activities. For the 2024 and 2025 tax years, the IRS has shifted from purely quantitative reporting to a narrative-driven requirement that demands project-level transparency.

The updated Form 6765 introduces several new sections that New York revenue offices are likely to adopt as the “gold standard” for audit substantiation:

Requires businesses to report the number of business components generating QREs and specific officer wages.

Requires an identification of each business component by name and type, along with a narrative description of the research activities performed, the names of individuals involved, and the specific information they sought to discover.

For New York businesses, particularly those in the Life Sciences program, these requirements create a “triple burden” of technical assessment, project-level costing, and multi-jurisdictional compliance management. A successful claim now requires the taxpayer to articulate their compliance in a format that the revenue office can immediately assess for indications of a deficient analysis.

Detailed Example: Calculating the R&D Innovation Subsidy

To demonstrate how the CIRA applies to the law in New York, we present a detailed case study of a hypothetical startup, “Silicon Hudson Inc.”

Scenario: Silicon Hudson Inc.

Silicon Hudson Inc. is a newly formed semiconductor research firm in the Hudson Valley with 8 full-time employees. In its second year of operation (2024), the company incurs the following costs for developing a new high-efficiency logic chip:

• Qualified NY Research Wages: $1,500,000
• Qualified NY Supplies: $300,000
• Computer Leasing (Cloud-based simulation): $200,000
• Total NY QREs: $2,000,000

The firm has been admitted to the Excelsior Jobs Program and is also a certified Qualified Life Sciences Company (due to its work on medical-grade sensors).

Step 1: Federal R&D Credit Calculation

The firm elects the Alternative Simplified Credit (ASC) method on federal Form 6765. For a new firm with no prior spending history, the credit is 6% of current-year QREs.

Federal R&D Credit = $2,000,000 x 6% = $120,000

Step 2: New York Excelsior R&D Credit Calculation

As an Excelsior participant in the semiconductor supply chain strategic industry, the firm is eligible for a credit of 50% of its federal credit, subject to a 7% cap on New York expenditures.

Excelsior R&D Component = $120,000 x 50% = $60,000

We verify this against the 7% cap:

$2,000,000 x 7% = $140,000

The $60,000 credit is well under the $140,000 cap and is fully allowable.

Step 3: Alternative – New York Life Sciences Credit Calculation

Alternatively, the firm could claim the Life Sciences credit if it chose not to use those specific expenses for Excelsior (as double-dipping is prohibited). With fewer than 10 employees, the rate is 20%.

Potential Life Sciences Credit = $2,000,000 x 20% = $400,000

This is under the $500,000 annual cap.

Step 4: Aggregate Savings

If the firm leverages the Life Sciences path (the more lucrative of the two), its total innovation subsidy would be:

• Federal Savings: $120,000
• New York Savings: $400,000
• Total Savings: $520,000 (a 26% effective discount on R&D spend).

Because the New York credit is fully refundable, Silicon Hudson Inc. would receive a $400,000 cash check from the state, providing vital runway for its next phase of development.

Statistics and Economic Impact Analysis

The fiscal impact of these credits is substantial, reflecting New York’s commitment to innovation-led growth. According to the FY 2025 Annual Report on New York State Tax Expenditures, the Life Sciences Research and Development Tax Credit has seen a marked increase in utilization.

The 2024 forecast suggests the program is operating at its maximum $10 million annual capacity. This is corroborated by ESD data indicating that over $50 million has been allocated to NYC’s biotech corridor since the program’s inception.

The Investment Tax Credit (ITC) for R&D property also remains a heavy-hitter, providing over $130 million annually in tax relief for businesses that invest in tangible research infrastructure.

Economic impact reports from PFM Group Consulting LLC highlight that these incentives have engendered a 27.1% growth in the number of life science companies and an 18.5% increase in sector-specific jobs between 2017 and 2022. This job growth rate is 13.3% higher than the national private sector average, suggesting that New York’s specific R&D policies are successfully attracting talent and capital.

Nuanced Insights: The Documentation Imperative and Audit Avoidance

The complexity of the New York R&D credit landscape necessitates a sophisticated approach to compliance. The “triple burden” mentioned earlier is not merely an administrative hurdle; it is the primary focus of DTF audits. Local guidance emphasizes that the ultimate success or failure of the research is irrelevant to the determination of eligibility; the credit is based on the effort to resolve technical uncertainty.

The Consistency Requirement

A frequent point of audit failure is the federal “consistency requirement” under Section 41(c)(5)(A). This rule mandates that QREs and gross receipts taken into account in the base period must be determined on a basis consistent with the determination of QREs for the current credit year. If a taxpayer includes a new category of expense in its current year claim (e.g., cloud computing costs), it must “reach back” into the base years and adjust those numbers upward to ensure the incremental increase is accurately measured. Failing to perform this adjustment often leads to a distortion of the credit and an subsequent disallowance upon audit.

Contemporaneous Recordkeeping

The Department of Taxation and Finance and the IRS both enforce a “contemporaneous” standard for documentation. Records must be created at the time the research is performed. Retroactive attempts to reconstruct R&D activities through interviews and “re-estimated” time sheets are frequently rejected by the courts.

New York businesses should maintain the following “audit-ready” file for every project:

Daily journals or project records describing technical challenges.

Dated records of testing protocols, prototypes, and failures.

A clear connection between an employee’s time, the specific business component they worked on, and the technical path they followed.

Contracts for outsourced research that clearly assign technical and economic risk to the taxpayer.

Final Thoughts

The Credit for Increasing Research Activities, when interpreted through the lens of New York’s tax policy, is more than a simple fiscal deduction; it is a vital engine for state economic transformation. By adopting the rigorous federal Section 41 standards while overlaying unique state-level benefits such as full refundability and industry-specific tiering, New York has created one of the most competitive environments for innovation in the United States.

However, the “meaning” of the credit is also shifting toward an era of unprecedented transparency. The 2024 and 2025 revisions to Form 6765 and the restoration of expensing under Section 174A have introduced a narrative requirement that forces businesses to document their “innovation journey” in real-time. For the New York professional, success in claiming these credits no longer rests solely on the total amount of research spending, but on the ability to demonstrate—through systematic records and project-level accounting—that their activities constitute a genuine process of experimentation aimed at solving the technical unknowns of the future. Actionable strategies, such as early admission to the Excelsior program and the proactive use of sales tax exemptions on R&D equipment, can further amplify the benefits of these incentives, ensuring that New York remains a leading destination for the technologies that will define the next century.